X

Drug Profile

Research programme: BCMA-targeted RNA therapeutics - Orna Therapeutics/Shanghai Simnova Biotechnology

Latest Information Update: 04 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orna Therapeutics; Shanghai Simnova Biotechnology
Developer Orna Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; RNA
Mechanism of Action Cell replacements; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Multiple myeloma

Most Recent Events

24 Jan 2025 Simnova and Orna expands strategic partnership to include BCMA-targeted RNA therapeutics
15 Jan 2025 Early research in Multiple myeloma in China (Parenteral), before January 2025
15 Jan 2025 Early research in Multiple myeloma in USA (Parenteral), before January 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com